Impact of Evolocumab on LDL-Cholesterol and Cardiovascular Outcomes in Patients With Established CVD: Systematic Review and Meta-Analysis.
Anika Goel, Muhammad Abdullah Naveed, Hemeesh Tandel et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis pooled randomised controlled trials of evolocumab in adults with established cardiovascular disease. Across nine trials enrolling 67,662 patients, evolocumab lowered LDL cholesterol by a mean difference of -57.73 mg/dL and was associated with fewer major adverse cardiovascular events (RR 0.53; 95% CI 0.40-0.71). Myocardial infarction and coronary revascularisation were also reduced, whereas cardiovascular mortality and stroke did not show statistically definitive reductions. Serious adverse events and neurocognitive effects were comparable between groups; injection-site reactions were more frequent with evolocumab.
Key findings
- LDL-C was reduced by a mean difference of -57.73 mg/dL with evolocumab.
- MACE was lower with evolocumab (RR 0.53; 95% CI 0.40-0.71), although endpoint and design heterogeneity warrants caution.
- Myocardial infarction (RR 0.74) and coronary revascularisation (RR 0.80) were significantly reduced.
- Serious adverse events and neurocognitive effects were comparable, while injection-site reactions were more frequent.
Why it matters
For secondary prevention, the pooled evidence links evolocumab’s substantial lipid lowering with fewer composite cardiovascular events and reductions in myocardial infarction and revascularisation. The absence of statistically definitive reductions in cardiovascular mortality and stroke, alongside heterogeneity in MACE definitions and study designs, means the overall benefit should be interpreted with appropriate caution.
What to keep in mind
The authors note heterogeneity in endpoint definitions and study designs, which limits confidence in the pooled MACE estimate.